TLDR Biotech

🧬 UK's NICE rejects both Biogen/Eisai and Eli Lilly's Alzheimer's drugs on cost grounds, while Novo Nordisk plots addiction plans for GLP-1s | TLDR Biotech for March 5 - 6, 2025 Other stories we've compiled in today's biotech & pharma space (+ 29 more): 👍 Neurotech nabs FDA approval for encapsulated cell therapy for macular telangiectasia type 2 💰 Frazier Life Sciences raising new venture fund (XII) 💼 Federal court approves $700M settlement from various drug companies to 1,000+ hospitals over opioid misconduct allegations Full newsletter at tldrbio(dot)tech!

🧬 Eli Lilly vets online applications for new sites, while Jazz Pharma acquires Chimerix for $935M | TLDR Biotech for March 4 - 5, 2025 Other stories we've compiled in today's biotech & pharma space (+ 33 more): ⬇️ Novo Nordisk drops Wegovy's price by 23% to $499 monthly for uninsured patients, 🛑 BioNTech's mRNA malaria vaccine slapped with FDA clinical hold 🤒 CDC boots hit the ground in Texas to assist with growing measles outbreak Full newsletter at tldrbio(dot)tech!

ADC (antibody-drug conjugate) and related antibodies are continuing to dominate the biotech space. And there's lots of attention given to these areas at BIO CHINA next week. Here's a brief overview of companies and topics presenting in this space: 🔬 𝐀𝐃𝐂 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ➡️ XDC Drugs Development (March 13) with Innolake Biopharm, WuXi XDC, Lepu Biopharma, and Boan Biotech ➡️ ADC Process & Quality (March 14) with Shanghai Hengrui, DualityBiologics, Doxee Biotech, and Meiyake ➡️ Pathological Research sessions featuring Qilu Pharmaceutical and Yilian Biotech ➡️ ADC Quality Topics with Jiangsu Mabwell, Miracogen, and Huaota Biopharm 🧬 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 (𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜, 𝐭𝐫𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜, 𝐓-𝐜𝐞𝐥𝐥 𝐞𝐧𝐠𝐚𝐠𝐞𝐫𝐬) 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ➡️ Platform Innovation (March 13) with Kangfang Biopharma, EpimAb, ImmuneOnco, and Chimagen Biosciences ➡️ TCE Research by Curon Bio, Elpiscience, Zencore Biologics, and GSK ➡️ Autoimmunity Applications with CytoCares and Qilu Pharmaceutical ➡️ Clinical Translation discussions led by MediLink and Simcere Pharmaceutical ✈️ I'm heading to Suzhou next week to attend BIO CHINA, a massive Chinese biotech and pharma conference, to try and understand the Chinese biotech space firsthand. 💡 TLDR Biotech is preparing a special report on the Chinese biotech ecosystem from interviews we'll conduct there. Any questions you want answered in this report? Drop your questions below or by email hello@tldrbio(dot)tech

🧬 China bans Illumina, while Sofinnova raises fresh €1.2B ($1.3B) VC fund | TLDR Biotech for March 3 - 4, 2025 Other stories we've compiled in today's biotech & pharma space (+ 29 more): ✅ BeiGene's PD-1 inhibitor Tevimbra lands another FDA-approved label in first-line esophageal squamous cell carcinoma 💰 Evotec nabs $20M payment as part of neuroscience collab with BMS 🙅 DOGE cuts leases for 30 FDA facilities across 23 states Full newsletter at tldrbio(dot)tech!

🧬 AbbVie gets in on obesity, and a new ADC contender launches with $187M | TLDR Biotech March 2 - 3, 2025 Other stories we've compiled in today's biotech & pharma space (+ 28 more): 🤝 Novo Nordisk & Gensaic partner to development cardiometabolic therapies using AI-enabled FORGE technology 🤔 Lexicon pushes ahead with pilavapadin Ph3 despite failing in Ph2b 👋 Top HHS spokesperson abrupt resignation after alleged clashes with RFK Jr. Full newsletter at tldrbio(dot)tech!

AI isn't just coming to drug discovery. It's already here. And while only a few AI-focused talks are on the BIO CHINA agenda next week, they might be the most consequential: - "From Algorithm to Clinic: AI-Powered Drug Discovery" (Insilico Medicine) - "AI+Robotics: Building the Lab of Future" (XtalPi) - "AI-driven mRNA drug development" (METiS Pharmaceuticals) - "AI in Drug Discovery Trends, Challenges and Opportunities" (Melbourne Medical School) - "Full chain AI empowers new drug innovation" Panel (Insilico Medicine, XtalPi, LexBio Therapeutics) I'm heading to Suzhou next week to see firsthand how these technologies are reshaping biopharma in the world's second-largest market. ➡️ TLDR Biotech is preparing a special report on the Chinese biotech ecosystem. What do you want to know about this space? Drop your questions below or by email hello@tldrbio(dot)tech

Eli Lilly and Company's up to $1.2B molecular glue pact with Magnet Biomedicine, while BMS cuts 200+ more jobs in New Jersey | TLDR Biotech Feb 27 - Mar 2, 2025 Other stories we've compiled in today's biotech & pharma space (+ 26 more): 💼 Eisai Co., Ltd. out-licences FGFR2-targeting tasurgratinib Greater China rights to SciClone Pharmaceuticals 💰 Merck offered $30M facility build grant by Delaware government 💬 Infectious disease experts plan independent vaccine advisory group pre-empting “eroding” of said committees by RFK Jr. Full newsletter at tldrbio(dot)tech!

🧬Vertex & Verve end gene-editing collab, and big pharma backs clinical trial diversity | TLDR Biotech Feb 26 - 27, 2025 Other stories we've compiled in today's biotech & pharma space (+ 31 more): 😮 BeiGene's BTK inhibitor surpasses AstraZeneca's BTK inhibitor in quarterly sales 🤝 Medigene & EpimAb Biotherapeutics co-developing TCR-guided T cell engagers for solid tumors ❌ Regeneron abandons accelerated approval ambitions for bispecific odronextamab in B cell lymphoma, instead focusing on follicular lymphoma Full newsletter on the TLDR Biotech website tldrbio(dot)tech

𝐂𝐞𝐥𝐥 𝐚𝐧𝐝 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 innovation in China is moving fast. Here are companies to watch (and what panels/talks they're participating in at BIO CHINA next month): 🧬 Cell Therapy Highlights: • Universal CAR-T development approaches (BRL Medicine 邦耀生物) • Next-gen universal cell therapy platforms (Neukio Biotherapeutics) • Innovative γδT cell therapies for solid tumors (北京清辉联诺生物科技有限责任公司-Unicet Biotech & PersonGen Biotherapeutics) • Commercial capacity design considerations for CAR-T (JW Therapeutics 药明巨诺, Juventas Cell Therapy Corp., IASO BioTherapeutics（驯鹿生物）) • Quality control strategies for cell therapy products (Oricell Therapeutics) • Novel CAR-NK approaches for oncology and "non-tumor indications" (ImBioRay Biomedicine) 🦠 Gene Therapy Highlights: • Production and QC strategies for recombinant AAVs (SineuGene Therapeutics) • Novel AAV capsid development platform (克睿基因 Cure Genetics) • In-situ neuro-regenerative gene therapy approaches (NeuExcell Therapeutics) • Oncolytic virus innovation for cancer treatment (ImmVira) There is a lot going on at BIO CHINA this year, and I'll be mentioning other companies in different modalities next week leading up to the event March 13 - 15 - stay tuned! #BIOCHINA2025 #BiotechInnovation #CellTherapy #GeneTherapy #CAR-T #Biotech

🧬Eli Lilly's $27B USA manufacturing commit, and Eikon nabs a $350M Series D | TLDR Biotech Feb 25 - 26, 2025 Other stories we've compiled in today's biotech & pharma space (+ 24 more): 🤝 HBM Alpha Therapeutics licenses CRH antibody therapy to undisclosed partner for up to $395M ✅ AstraZeneca touts positive Ph3 data for camizestrant (estrogen receptor degrader) in certain forms of breast cancer 😬 Idorsia hits dire funding straits as global rights sale of hypertension drug Tryvio falls through Get the full newsletter on the TLDR Biotech website at https://lnkd.in/gHM_uFwR